Previous 10 | Next 10 |
Volpara Collaborates With Invitae Corporation, Leading Genetics Company Collaboration Expands Access to Genetic Testing and Risk Assessment Capabilities Available through Volpara's Breast Health Platform PR Newswire SEATTLE , July 22, 2021 /PRNewswire/ -- ...
Pacific Biosciences of California (PACB) gains 2.5% premarket after signing a merger agreement to acquire Omniome, a San Diego-based company developing a highly differentiated short-read sequencing platform capable of delivering high accuracy. Under the terms of the agreement, PacBi...
Invitae to Announce Second Quarter 2021 Financial Results on Tuesday, August 3, 2021 PR Newswire SAN FRANCISCO , July 20, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its second...
Collaboration to develop production-scale HiFi Sequencing platform expected to Include technology from Omniome, Inc. Combining both highly accurate long and short read sequencing technologies expected to provide deeper clinical insights and lower the overall cost of an...
After the rally in May and June, many growth stocks have dropped again in value recently. I propose six stocks to buy the dip for growth investors. The stocks I have picked are Pinterest, Fiverr, Teladoc Health, PubMatic, Peloton and Alibaba. For further details see: 6 G...
A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. Focus on IDNA. A list of cheap stocks. For further details see: IDNA And Healthcare Dashboard For July
Diagnostics stocks hit a rough patch this week. Shares of Bionano Genomics (NASDAQ: BNGO) were down 13.5% for the week as of the market close on Thursday. Invitae (NYSE: NVTA) stock was off by 12% over the last four days, while Opko Health (NASDAQ: OPK) shares have t...
Invitae (NYSE: NVTA) is on a mission "to bring comprehensive genetic information to mainstream medicine to improve healthcare for billions." In medical terms, Invitae can help the roughly one in six people who have a medical condition with an underlying genetic component. In financi...
Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...
Biotech company Invitae’s (NVTA) substantial revenue growth in its last reported quarter, and its progress in ushering personalized health monitoring into the mainstream, have impressed investors. However, the company’s top-line growth is not expected to translate into profitabi...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...